These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11131000)

  • 1. Intravenous immunoglobulin treatment of immunodeficiency disorders.
    Schwartz SA
    Pediatr Clin North Am; 2000 Dec; 47(6):1355-69. PubMed ID: 11131000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease.
    Wasserman RL; Lumry W; Harris J; Levy R; Stein M; Forbes L; Cunningham-Rundles C; Melamed I; Kobayashi AL; Du W; Kobayashi R
    J Clin Immunol; 2016 Aug; 36(6):590-9. PubMed ID: 27324887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy.
    Kaveri SV; Maddur MS; Hegde P; Lacroix-Desmazes S; Bayry J
    Clin Exp Immunol; 2011 Jun; 164 Suppl 2(Suppl 2):2-5. PubMed ID: 21466545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
    Pac M
    Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study.
    Shemer A; Kivity S; Shoenfeld Y
    Transfusion; 2018 Feb; 58(2):430-438. PubMed ID: 29193136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.
    Costa-Carvalho BT; Sullivan KE; Fontes PM; Aimé-Nobre F; Gonzales IGS; Lima ES; Granato C; de Moraes-Pinto MI
    J Clin Immunol; 2018 Jul; 38(5):628-634. PubMed ID: 30006913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in IVIG use at a tertiary care Canadian center and impact of provincial use mitigation strategies: 10-year retrospective study with interrupted time series analysis.
    Murphy MSQ; Tinmouth A; Goldman M; Chassé M; Colas JA; Saidenberg E; Shehata N; Fergusson D; Forster AJ; Wilson K
    Transfusion; 2019 Jun; 59(6):1988-1996. PubMed ID: 30916409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
    Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
    J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of intravenous immunoglobulin preparations (IVIG) in treatment of primary cell immunodeficiencies].
    Siwińska-Gołebiowska H; Czerwińska-Kartowicz I; Markiewicz K
    Postepy Hig Med Dosw; 2002; 56 Suppl():33-40. PubMed ID: 12661412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.
    Schroeder HW; Dougherty CJ
    Infection; 2012 Dec; 40(6):601-11. PubMed ID: 22968971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human intravenous immunoglobulin in primary and secondary antibody deficiencies.
    Stiehm ER
    Pediatr Infect Dis J; 1997 Jul; 16(7):696-707. PubMed ID: 9239774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.
    Ferrara G; Zumla A; Maeurer M
    Am J Med; 2012 Oct; 125(10):1036.e1-8. PubMed ID: 22608788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. I.V. immunoglobulin therapy for infectious diseases.
    Drug Ther Bull; 2010 May; 48(5):57-60. PubMed ID: 20447982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients.
    Lamari F; Karamanos NK; Papadopoulou-Alataki E; Kanakoudi-Tsakalidou F; Dimitracopoulos G; Anastassiou ED
    J Pharm Biomed Anal; 2000 Jul; 22(6):1029-36. PubMed ID: 10857572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome.
    Cheng YK; Decker PA; O'Byrne MM; Weiler CR
    Ann Allergy Asthma Immunol; 2006 Sep; 97(3):306-11. PubMed ID: 17042135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution physicochemical characterization of different intravenous immunoglobulin products.
    Washburn N; Meccariello R; Hu S; Hains M; Bhatnagar N; Sarvaiya H; Kapoor B; Schaeck J; Pino I; Manning A; Lansing JC; Bosques CJ
    PLoS One; 2017; 12(7):e0181251. PubMed ID: 28759653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.